|
|
|
|
|
| Fosfomycin Resistance in Avian Pathogenic Escherichia coli Isolates |
| JIN Wen-jie, ZHENG Zhi-ming, WANG Qian-qian, QIN Ai-jian, SHAO Hong-xia , QIAN Kun |
1.Key Lab for Avian Preventive Medicine, Ministry of Education/College of Veterinary Medicine, Yangzhou University, Yangzhou 225009,
P.R.China2.Circulation Industry Promotion Center, Ministry of Commerce, Beijing 100070, P.R.China
3.Animal Disease Preventive and Control Center of Yangzhou, Yangzhou 225009, P.R.China |
|
|
|
摘要 Fosfomycin, a broad-spectrum antibiotic against both Gram-positive and Gram-negative bacteria, is very important in the clinic but many fosfomycin-resistant bacteria have been isolated from patients. In this study, the resistance mechanism of three fosfomycin-resistant avian pathogenic Escherichia coli (APEC) strains (JE1, IF7 and CD11) isolated from septicemic chickens were analyzed. The results showed that their fosfomycin-resistance mechanisms were different. An alteration in the glpT transport system was the main reason of the fosfomycin-resistance mechanisms of strain IF7. Compared with the control stain BL21, the capacity of fosfomycin-uptake was low in all these three stains (JE1>IF7>CD11). Sequence results of murA showed that there were more than 10 sites of nucleotide mutation, but only one amino acid mutation T116A showed in CD11. Real-time detection test showed that the expression level of the murA gene of the three stains was significantly increased (four times increase in strain CD11 and two times increase in strains JE1 and IF7). The transformation and recombinant test showed that the recombinant bacteria with the murA of JE1 and CD11 showed high minimal inhibitory concentration (MIC) against fosfomycin. From the results of this research, it showed that most of the fosfomycinresistance mechanisms once showed in patient bacteria have appeared in the APEC strains and the fosfomycin-resistance mechanism of the three APEC isolates was different.
Abstract Fosfomycin, a broad-spectrum antibiotic against both Gram-positive and Gram-negative bacteria, is very important in the clinic but many fosfomycin-resistant bacteria have been isolated from patients. In this study, the resistance mechanism of three fosfomycin-resistant avian pathogenic Escherichia coli (APEC) strains (JE1, IF7 and CD11) isolated from septicemic chickens were analyzed. The results showed that their fosfomycin-resistance mechanisms were different. An alteration in the glpT transport system was the main reason of the fosfomycin-resistance mechanisms of strain IF7. Compared with the control stain BL21, the capacity of fosfomycin-uptake was low in all these three stains (JE1>IF7>CD11). Sequence results of murA showed that there were more than 10 sites of nucleotide mutation, but only one amino acid mutation T116A showed in CD11. Real-time detection test showed that the expression level of the murA gene of the three stains was significantly increased (four times increase in strain CD11 and two times increase in strains JE1 and IF7). The transformation and recombinant test showed that the recombinant bacteria with the murA of JE1 and CD11 showed high minimal inhibitory concentration (MIC) against fosfomycin. From the results of this research, it showed that most of the fosfomycinresistance mechanisms once showed in patient bacteria have appeared in the APEC strains and the fosfomycin-resistance mechanism of the three APEC isolates was different.
|
|
Received: 18 July 2012
Accepted:
|
| Fund: This work was supported by the grants (30800822) from NSFC, the Innovative Research Funding of Yangzhou University, China (2011CXJ067), also sponsored by Qing Lan Project, the Program for Changjiang Scholars, the Innovative Research Team in University, Ministry of Education of China (IRT0978), and the Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, China (PAPD). |
|
Corresponding Authors:
Correspondence QIN Ai-jian, E-mail: aijian@yzu.edu.cn
E-mail: aijian@yzu.edu.cn
|
| About author: JIN Wen-jie, E-mail: wenjiejin1@163.com |
Cite this article:
JIN Wen-jie, ZHENG Zhi-ming, WANG Qian-qian, QIN Ai-jian, SHAO Hong-xia , QIAN Kun.
2012.
Fosfomycin Resistance in Avian Pathogenic Escherichia coli Isolates. Journal of Integrative Agriculture, 12(12): 2051-2057.
|
| [1]Arca P, Reguera G, Hardisson C. 1997. Plasmid-encodedfosfomycin resistance in bacteria isolated from theurinary tract in a multicentre survey. Journal ofAntimicrobial Chemotherapy, 40, 393-399.[2]Baum E Z, Montenegro D A, Licata L, Turchi I, Webb G C,Foleno B, Bush K. 2001. Ident if icat ion andcharacterization of new inhibitors of the Escherichiacoli MurA enzyme. Antimicrobial Agents andChemotherapy, 45, 3182-3188.[3]Brown E D, Vivas E I, Walsh C T, Kolter R. 1995. MurA(MurZ), the enzyme that catalyzes the first committedstep in peptidoglycan biosynthesis, is essential inEscherichia coli. Journal of Bacteriology, 177, 4194-4197.[4]Cassidy P J, Kahan F M. 1973. A stable enzymephosphoenolpyruvateintermediate in the synthesis ofur idine - 5 ´-diphospho-N- a c e tyl -2-amino- 2 -deoxyglucose 3-O-enolpyruvyl ether. Biochemistry, 12,1364-1374.[5]Christensen B G, Leanza W J, Beattie T R, Patchett A A,Arison B H, Ormond R E, Kuehl FA, Albers-SchonbergJr G, Jardetzky O. 1969. Phosphonomycin: structure andsynthesis. Science, 166, 123-125.[6]Du W, Brown J R, Sylvester D R, Huang J, Chalker A F, SoC Y, Holmes D J, Payne D J, Wallis N G. 2000. Twoactive forms of UDP-N-acetylglucosamine enolpyruvyltransferase in Gram-positive bacteria. Journal ofBacteriology, 182, 4146-4152.[7]Garcia-Lobo J M, Ortiz J M. 1982. Tn292l, a transposonencoding fosfomycin resistance. Journal ofBacteriology, 151, 477-479.[8]Hendlin D, Stapley E O, Jackson M , Wallick H, Miller A K,Wolf F J, Miller TW, Chaiet L, Kahan FM, Foltz E L, etal. 1969. Phosphonomycin, a new antibiotic producedby strains of streptomyces. Science, 166, 122-123.[9]Horii T, Kimura T, Sato K, Shibayama K, Ohta M. 1999.Emergence of fosfomycin-resistant isolates of Shigalike toxin-producing Escherichia col i O26 .Antimicrobial Agents and Chemotherapy, 43, 789-793.[10]Jin W J, Zhang Y M, Qin A J, Shao H X, Liu Y L, Wang J,Wang Q Q. 2008. Distribution of virulence-associatedgenes of avian pathogenic Escherichia coli isolates inChina. Agricultural Sciences in China, 7, 1511-1515.[11]Kahan F M, Kahan J S, Cassidy P J, Kropp H. 1974. Themechanism of action of fosfomycin phosphonomycin.Annals of the New York Academy of Sciences, 235,364-386.[12]Lell B, Ruangweerayut R, Wiesner J, Wiesner J, MissinouM A, Schindler A, Baranek T, Hintz M, Hutchinson D,Jomaa H, et al. 2003. Fosmidomycin, a novelchemotherapeutic agent for malaria. AntimicrobialAgents and Chemotherapy, 47, 735-738.[13]Lindgren V, Rutberg L. 1976. Genetic control of the glpsystem in Bacillus subtilis. Journal of Bacteriology,127, 1047-1057.[14]Marquardt J L, Siegele D A, Kolter R , Walsh C T. 1992.Cloning and sequencing of Escherichia coli murZ andpurification of its product, a UDP-N-acetylglucosamineenolpyruvyl transferase. Journal of Bacteriology, 174,5748-5752.[15]McCoy A J, Sandlin R C, Maurelli A T. 2003. In vitro and invivo functional activity of Chlamydia MurA, a UDP-Nacetylglucosamineenolpyruvyl transferase involved inpeptidoglycan synthesis and fosfomycin resistance.Journal of Bacteriology, 185, 1218-1228.[16]Merkel T J, Nelson D M, Brauer C L, Kadner R J. 1992.Promoter elements required for positive control oftranscription of the Escherichia coli uhpT gene.Journal of Bacteriology, 174, 2763-2770.[17]Miller R A, Reimschuessel R. 2006. Epidemiologic cutoffvalues for antimicrobial agents against Aeromonassalmonicida isolates determined by frequencydistributions of minimal inhibitory concentration anddiameter of zone of inhibition data. American Journalof Veterinary Research, 67, 1837-1843.[18]Nilsson A I, Berg O G, Aspevall O, Kahlmeter G, AnderssonD I. 2003. Biological costs and mechanisms offos fomyc in res is t ance in Escher ichia col i .Antimicrobial Agents and Chemotherapy, 47, 2850- 2858.Rao N N, Roberts M F, Torriani A, Yashphe J. 1993. Effectof glpT and glpD mutations on expression of the phoAgene in Escherichia coli. Journal of Bacteriology, 175,74-79.[19]Sambrook J, Russell D W. 2006. The Condensed ProtocolsFrom Molecular Cloning: a Laboratory Manual. ColdSpring Harbor Laboratory Press, Cold Spring Harbor,N.Y.Savini V, Catavitello C, Bianco A, Balbinot A, D’AntonioD. 2009. Epidemiology, pathogenicity and emergingresistances in Staphylococcus pasteuri: from mammalsand lampreys, to man. Recent Patents on Anti-InfectiveDrug Discovery, 4, 123-129.[20]Schito G C, Naber K G, Botto H, Palou J, Mazzei T, GualcoL, MarcheseA. 2009. The ARESC study: an internationalsurvey on the antimicrobial resistance of pathogensinvolved in uncomplicated urinary tract infections.International Journal of Antimicrobial Agents, 34, 407-413.[21]Shimizu M, Shigeobu F, Miyakozawa I, Nakamura A, SuzukiM, Mizukoshi S, O’Hara K, Sawai T. 2000. NovelFosfomycin resistance of Pseudomonas aeruginosaclinical isolates recovered in Japan in 1996.Antimicrobial Agents and Chemotherapy, 44, 2007-2008.[22]Smeyers Y G, Hernandez-Laguna A, von Carstenn-Lichterfelde C. 1983. Quantum mechanical calculationsuseful for determining the mechanism of action offosfomycin. Journal of Pharmaceutical Sciences, 72,1011-1014.[23]Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K,Terada S, Muratani T, Matsumoto T, Nakahama C,Tomono K. 2010. Molecular mechanisms of fosfomycinresistance in clinical isolates of Escherichia coli.International Journal of Antimicrobial Agents, 35, 333-337.[24]Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y.2010. Prevalence of fosfomycin resistance among CTXM-producing Escherichia coli clinical isolates in Japanand identification of novel plasmid-mediatedfosfomycin-modifying enzymes. Antimicrobial Agentsand Chemotherapy, 54, 3061-3064.[25]Wiesner J, Henschker D, Hutchinson D B, Beck E, JomaaH. 2002. In vitro and in vivo synergy of fosmidomycin,a novel antimalarial drug, with clindamycin.Antimicrobial Agents and Chemotherapy, 46, 2889-2894.[26] |
| No Suggested Reading articles found! |
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
